
ASCO's TAPUR Study Expands to Enroll Patients Receiving Immunotherapy
With an expansion that includes immunotherapy combination treatments, the American Society of Clinical Oncology (ASCO)’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study has now grown to 500 participants and 16 therapies.
With an expansion that includes immunotherapy combination treatments, the American Society of Clinical Oncology (ASCO)’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study has now grown to 500 participants and 16 therapies.
“This study just reached a key milestone and we're excited to explore these treatments further,” said ASCO chief medical officer Richard L. Schilsky, MD, FACP, FASCO. “While no conclusions about drug efficacy should be drawn at this point, we are very pleased with the growth and expansion of the TAPUR Study.”
The expansion now adds patients to the following study arms to TAPUR:
- Patients with ovarian cancer with KRAS, NRAS, and BRAF wildtype variants treated with cetuximab
- Patients with breast cancer with a high tumor mutation burden treated with pembrolizumab
- Patients with colorectal cancer with a BRAF V600E mutation treated with vemurafenib plus cobimetinib
- Patients with non—small cell lung cancer with CDKN2A deletion or mutation treated with palbociclib as monotherapy
The following study cohort, however, will be permanently closed:
- Patients with pancreatic cancer with CDKN2A loss or mutation treated with palbociclib as monotherapy
TAPUR, which provides patients access to drugs at no cost, is
According to the ASCO
“The TAPUR trial gives us the chance to [apply] the technology and the science, and apply it to patients in real time, with everybody agreeing that they’re going to have access to the medicine, that they’re going to have payment for the treatments, and that the data are going to be available,”
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.